Neil Kumar's BridgeBio lines up subsidiary No. 9 with a $27M shot at TTR amyloidosis
Neil Kumar — ex-McKinsey, ex-Third Rock, ex-BD guy at MyoKardia — set out to build a different kind of biotech when he started BridgeBio a couple of years ago.
Looking at the money that was already available for platform plays and late-stage drug work, he was interested in finding new money to go after early-stage assets. So he adopted an oil company strategy, laying out the prospects for a biotech outfit that would focus on what we’ve learned from genetics discovery over the past decade, then plucking single assets that could be compartmentalized in subsidiaries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.